Skip to content
DataLookout
Menu

NCT06402201

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Study completion moved earlier from Dec 31, 2027 to Apr 5, 2027
    • Study sites: 20 to 18
  2. Notable Primary completion pushed from Jun 30, 2026 to Dec 30, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Study sites: 18 to 20
    • Secondary endpoints: details revised at 1 of 14 entries
    • Study description expanded, about 5 words
  3. Minor Study sites: 17 to 18v14
  4. Minor Site details revised at 17 of 17 sitesv13
  5. Minor Site details revised at 2 of 17 sitesv12
Show 9 earlier versionsHide 9 earlier versions
  1. Minor Site details revised at 5 of 17 sitesv11
  2. Minor Study sites: 16 to 17v10
  3. Minor Study sites: 5 to 16v9
  4. Minor Site details revised at 1 of 5 sitesv7
  5. Minor Site contacts updated at 2 of 5 sitesv6
  6. Minor Site details revised at 1 of 5 sitesv5
  7. Minor Site details revised at 1 of 5 sitesv4
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 15, 2024 to May 24, 2024
    • Site details revised at 5 of 5 sites
    v3
  9. Study Status, Contacts/Locationsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Presence of dose limiting toxicities (DLTs)
Timeframe: From first dose to DLT period (21 days)
Incidence and severity of (serious) adverse events ([S]AEs)
Timeframe: From first dose to 90 days after the last dose
Anti-tumor response: Overall Response Rate (ORR)
Timeframe: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

Secondary (14)

Disease control rate (DCR)
Duration of response (DOR)
Progression-free Survival (PFS)
Overall Survival (OS)
Maximum serum concentration of CDR404 (Cmax)
Show 9 moreShow less
Time to maximum serum concentration of CDR404 (Tmax)
Trough serum concentration of CDR404 (Ctrough)
Half-life of CDR404 (t1/2)
Area under the CDR404 serum concentration over time curve (AUC0-T)
Volume of CDR404 distribution (Vd)
Average serum concentration of CDR404 (Cavg)
Serum drug levels of CDR404 at steady state (CL)
Accumulation ratio of CDR404 (Rac)
Immunogenicity

Arms and interventions

CDR404Experimental

Dose escalation

Biologicals: CDR404

Sites

18 sites in 6 countries

Spain 6, Belgium 4, United Kingdom 3, Italy 2, United States 2, Denmark 1